«Factor recombinante VIIa como terapia complementaria en el control del sangrado en pacientes de trauma con lesiones severas: Ensayo clínico randomizado dos paralelo, control placebo, doble ciego. «
Boffard, Kenneth David MD; Riou, Bruno MD, PhD; Warren, Brian MD; Choong, Philip Iau Tsau MD; Rizoli, Sandro MD; Rossaint, Rolf MD; Axelsen, Mads MD; Kluger, Yoram MD; for the NovoSeven Trauma Study Group
Background: Uncontrolled bleeding is a leading cause of death in trauma. Two randomized, placebo-controlled, double-blind trials (one in blunt trauma and one in penetrating trauma) were conducted simultaneously to evaluate the efficacy and safety of recombinant factor VIIa (rFVIIa) as adjunctive therapy for control of bleeding in patients with severe blunt or penetrating trauma.
Methods: Severely bleeding trauma patients were randomized to rFVIIa (200, 100, and 100 [mu]g/kg) or placebo in addition to standard treatment. The first dose followed transfusion of the eighth red blood cell (RBC) unit, with additional doses 1 and 3 hours later. The primary endpoint for bleeding control in patients alive at 48 hours was units of RBCs transfused within 48 hours of the first dose.
Results: Among 301 patients randomized, 143 blunt trauma patients and 134 penetrating trauma patients were eligible for analysis. In blunt trauma, RBC transfusion was significantly reduced with rFVIIa relative to placebo (estimated reduction of 2.6 RBC units, p = 0.02), and the need for massive transfusion (>20 units of RBCs) was reduced (14% vs. 33% of patients; p = 0.03). In penetrating trauma, similar analyses showed trends toward rFVIIa reducing RBC transfusion (estimated reduction of 1.0 RBC units, p = 0.10) and massive transfusion (7% vs. 19%; p = 0.08). Trends toward a reduction in mortality and critical complications were observed. Adverse events including thromboembolic events were evenly distributed between treatment groups.
Conclusion: Recombinant FVIIa resulted in a significant reduction in RBC transfusion in severe blunt trauma. Similar trends were observed in penetrating trauma. The safety of rFVIIa was established in these trauma populations within the investigated dose range.
Trauma-Injury Infection & Critical Care. 59(1):8-18, July 2005.